HALIFAX, Nova Scotia, April 23, 2020 -- MedMira Inc. (MedMira) (TSXV: MIR), announced today that it had submitted the
notification for the Emergency Use Authorization application offered by the U.S. Food and Drug Administration (FDA) for its
newest member of its Reveal line of products for antibody testing. The FDA policy announced on March 16, 2020 permits
TM
MedMira to begin U.S. sales of REVEALCOVID-19 total antibody test immediately while it awaits FDA clearance under Emergency Use Authorization (EUA).
“Completion of the validation, and the notification to the FDA is a key step in our efforts to bring our newest test to market in
an attempt to help the COVID-19 pandemic situations. The Company’s full submission for EUA is currently in preparation.”
®
said Hermes Chan, CEO, “Our Rapid Vertical Flow technology, with no timer or reader requirement, allows all our rapid tests
to be used in various settings and provides an immediate clearly visible result.”